Review finds limited regulatory acceptability of mesocosm studies for macrophytes, suggesting improved experimental design is necessary.
Mesocosms can be used in higher tier aquatic risk assessments to assess the impact of Plant Protection Products (PPPs) on macrophytes. However, it is unclear whether these expensive and time consuming higher tier studies influence regulatory outcomes. This review highlights common shortcomings in the experimental design of mesocosm studies, with the aim of maximising the regulatory value of future mesocosm studies. Fourteen mesocosm studies, which have been submitted for the regulatory risk assessments for macrophytes in the EU or GB, were identified and reviewed. Results show that only five of the 14 mesocosm studies were deemed acceptable by the regulatory authorities, suggesting that mesocosm studies are not currently being used to their full potential. Issues with the submitted studies include not following a realistic PPP exposure profile (including incorrect dose timings and dilutions), only using one macrophyte morphology, not leaving enough time for the macrophytes to establish and a lack of replicates which increases variability within treatments. Glyceria maxima and Myriophyllum spicatum were frequently the most sensitive macrophyte species, whilst dry weight was often the most sensitive and least variable endpoint. Even though mesocosms provide the opportunity for recovery and community responses to be observed, such information has not been used by regulatory authorities. Future regulatory mesocosm studies can build upon the shortcomings highlighted here, providing a greater chance of regulatory impact.
No takes yet. Share an insight, caveat, or question.
Law et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: